News & Updates
Filter by Specialty:
Weight status influences urinary function recovery after radical prostatectomy
Among prostate cancer patients, those without obesity are more likely to experience earlier recovery in urinary function after radical prostatectomy and have better sexual function both before and after the procedure, as reported in a study.
Weight status influences urinary function recovery after radical prostatectomy
10 Mar 2023
BP awareness, drug adherence help prevent death, morbidity in stroke patients
Encouraging people to check their blood pressure (BP) regularly and boost adherence to antihypertensive medications can potentially reduce stroke mortality and morbidity, suggests a study. Improving the literacy level and reducing the smoking rate may help achieve these goals.
BP awareness, drug adherence help prevent death, morbidity in stroke patients
10 Mar 2023
RAS-modifying drugs reduce CVD risk in lupus patients
Use of antihypertensive agents that modify the renin-angiotensin system (RAS) helps lower the risk of cardiovascular disease (CVD) in patients with systemic lupus erythematosus (SLE), suggests a study.
RAS-modifying drugs reduce CVD risk in lupus patients
10 Mar 2023
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
10 Mar 2023
mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.
mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
10 Mar 2023
Novel intravaginal device for postpartum bleeding passes muster in phase II trial
A less invasive intravaginal device that facilitates bimanual uterine compression appears to work well in the treatment of postpartum haemorrhage, according to the results of a phase II trial.
Novel intravaginal device for postpartum bleeding passes muster in phase II trial
09 Mar 2023
Selgantolimod well tolerated, induces serologic changes in CHB
Treatment with the oral Toll-like receptor 8 (TLR8) agonist selgantolimod once weekly for 24 weeks is well tolerated and generally safe in patients with chronic hepatitis B (CHB) under viral suppression, according to a recent study.
Selgantolimod well tolerated, induces serologic changes in CHB
09 Mar 2023
Gene links breast cancer to stress, circadian disruption
Two researchers from the Philippines have discovered a gene the connects breast cancer development to stress and body clock disruption. In a recent study, they have shown the mechanism behind hormone and circadian regulation of the tumour-suppressor gene, Krüppel-like factor 9 (KLF9), and its effect on breast cancer progression.